News from pharmathene, inc

Jun 09, 2014, 10:30 ET

PharmAthene Granted U.S. Patent For Recombinant Bioscavenger

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to...

Jun 04, 2014, 10:30 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The FDA Medical Countermeasures Initiative Symposium

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax® anthrax vaccine program were recently presented at the 2014...

May 29, 2014, 10:29 ET

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax® anthrax vaccine program were presented...

May 08, 2014, 16:02 ET

PharmAthene Reports First Quarter 2014 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Apr 07, 2014, 09:00 ET

PharmAthene Updates Status Of SparVax® Anthrax Vaccine Contract

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS),...

Apr 01, 2014, 14:42 ET

PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were...

Mar 11, 2014, 16:00 ET

PharmAthene Reports Year-End 2013 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Mar 10, 2014, 12:20 ET

PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014

 PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats,...

Dec 16, 2013, 08:00 ET

PharmAthene Receives FDA Notification On SparVax®

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced...

Dec 02, 2013, 09:00 ET

PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with...

Nov 11, 2013, 09:47 ET

New PharmAthene SparVax® Anthrax Vaccine Data Published In Clinical and Vaccine Immunology

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Nov 07, 2013, 16:30 ET

PharmAthene Reports Third Quarter 2013 Financial And Operational Results

  Recent Highlights - On track to commence SparVax® Phase 2 clinical trial - Presented new SparVax® anthrax vaccine...

Sep 13, 2013, 08:34 ET

New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge

PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax...

Sep 09, 2013, 08:20 ET

PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission

PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange...

Sep 06, 2013, 13:00 ET

PharmAthene Presents New SparVax® Data At The Bacillus - ACT 2013 International Anthrax Conference

 PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were...

Sep 03, 2013, 08:00 ET

PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats,...

Aug 07, 2013, 16:00 ET

PharmAthene Reports Second Quarter 2013 Financial And Operational Results

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today...

Aug 05, 2013, 15:32 ET

PharmAthene to Host Second Quarter 2013 Conference Call and Webcast on Wednesday, August 7, 2013

 PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats,...

Aug 01, 2013, 07:05 ET

PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets

 PharmAthene, Inc. (NYSE MKT: PIP) and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company,...

Jul 03, 2013, 15:14 ET

PharmAthene To Present At The JMP Securities 2013 Healthcare Conference On Wednesday, July 10, 2013

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer